Sanofi to Present Extensive Immunology Data at AAAAI 2025, Highlighting Dupixent and Pipeline Advances
核心洞察
Sanofi will showcase 24 abstracts at AAAAI (搜索) 2025, including new pooled results from Dupixent's phase 3 trials in chronic spontaneous urticaria (搜索) and data across multiple inflammatory conditions.
New phase 2 data for rilzabrutinib, an investigational oral BTK inhibitor, will demonstrate its potential in treating moderate-to-severe chronic spontaneous urticaria (搜索) patients.
The presentations will include four oral sessions and a late-breaking poster, covering diseases such as asthma (搜索), COPD (搜索), CRSwNP, and eosinophilic esophagitis (搜索).
Sanofi is set to make a significant impact at the upcoming American Academy of Allergy, Asthma (搜索) and Immunology (AAAAI (搜索)) Annual Meeting in San Diego, presenting an extensive portfolio of research across multiple therapeutic areas. The conference, scheduled for February 28 – March 3, 2025, will feature 24 abstracts from the company's immunology program.
Advancing Treatment in Chronic Spontaneous Urticaria
A highlight of the presentations will be new pooled results from the LIBERTY-CSU CUPID (搜索) phase 3 program, investigating Dupixent's potential in chronic spontaneous urticaria (搜索) (CSU). The data, presented in partnership with Regeneron, will focus on patients whose symptoms remain uncontrolled with H1-antihistamines.
Dr. Alyssa Johnsen, Global Therapeutic Area Head of Immunology and Oncology Development, emphasized the significance of these presentations: "Our robust presence at AAAAI (搜索) emphasizes the progress of our clinical development in immunology and underscores our commitment to transforming treatment paradigms in immunoscience."
Expanding Dupixent's Clinical Evidence
The conference will showcase multiple studies demonstrating Dupixent's efficacy across various inflammatory conditions:
- The VESTIGE phase 4 study will present new findings on improvements in small airway dysfunction in patients with uncontrolled moderate-to-severe asthma
- Pooled results from the NOTUS and BOREAS phase 3 studies in adults with COPD and type 2 inflammation
- Post-hoc analysis from the LIBERTY EoE TREET phase 3 study examining outcomes in adults and adolescents with eosinophilic esophagitis
Additionally, five real-world evidence presentations will demonstrate Dupixent's impact across three disease states, providing valuable insights into its practical clinical applications.
Innovation in BTK Inhibition
The RILECSU (搜索) phase 2 study will present new analyses of rilzabrutinib, Sanofi's novel oral BTK inhibitor, in treating moderate-to-severe CSU. Key data will include:
- Effects on angioedema over a 12-week period
- Subgroup analysis examining efficacy in patients with and without allergic comorbidities
This research represents a potential breakthrough in oral therapy for CSU patients, though rilzabrutinib remains investigational and awaits regulatory evaluation.
Comprehensive Disease Coverage
The presentations span multiple therapeutic areas, including:
- Asthma management and clinical remission
- COPD treatment outcomes
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Eosinophilic esophagitis
- Atopic dermatitis
- Chronic spontaneous urticaria
Each presentation aims to provide healthcare professionals with new insights into treatment approaches and patient outcomes across these challenging conditions.